# 3B Blackbio Dx (NSE: 3BBLACKBIO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/3BBLACKBIO · Pivot · prices to 22 Oct 2026

3B Blackbio Dx (NSE: 3BBLACKBIO) closed at ₹1,316.60 on 22 Oct 2026, down 0.47% on the day. With a market capitalisation of ₹1,130 Cr, it ranks 1394th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Diversified sector.

Its return on equity was 18.1% in FY26. Its 52-week range is ₹1,085.00 (2 Jun 2026) to ₹1,740.00 (30 Sep 2026); the last close is 24.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹35 Cr (+57.5% year on year) and net profit ₹10 Cr (+21.9%), on a consolidated basis. Promoters held 40.95% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,316.60 |
| Market cap | ₹1,130 Cr |
| ROE | 18.1% (FY26) |
| ROCE | 22.6% (FY26) |
| Debt to equity | 0.01 |
| 52-week high | ₹1,740.00 (30 Sep 2026) |
| 52-week low | ₹1,085.00 (2 Jun 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹35 Cr | +57.5% | ₹10 Cr | +21.9% | ₹11.44 |
| Q3 FY26 | ₹50 Cr | +98.3% | ₹22 Cr | +66.2% | ₹26.19 |
| Q2 FY26 | ₹34 Cr | +16.3% | ₹15 Cr | +1.2% | ₹17.55 |
| Q1 FY26 | ₹22 Cr | +14.4% | ₹13 Cr | +11.9% | ₹14.76 |
| Q4 FY25 | ₹23 Cr | −2.2% | ₹8 Cr | −8.5% | ₹9.38 |
| Q3 FY25 | ₹25 Cr | +43.7% | ₹14 Cr | +58.5% | ₹15.75 |
| Q2 FY25 | ₹29 Cr | +52.0% | ₹15 Cr | +95.8% | ₹17.35 |
| Q1 FY25 | ₹19 Cr | +36.1% | ₹11 Cr | +56.7% | ₹13.19 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹96 Cr | ₹48 Cr |
| FY24 | ₹74 Cr | ₹32 Cr |
| FY23 | ₹62 Cr | ₹26 Cr |
| FY22 | ₹81 Cr | ₹32 Cr |
| FY21 | ₹227 Cr | ₹114 Cr |
| FY20 | ₹29 Cr | ₹8 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 40.95%
- Foreign institutions: 2.50%
- Domestic institutions: 2.15%
- Non-institutions: 54.40%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [BOMDYEING](https://app.pivotnow.in/stock/BOMDYEING) | ₹92.13 | ₹1,903 Cr | — | — |
| [Sika Interplant Systems](https://app.pivotnow.in/stock/SIKA) | ₹894.90 | ₹1,897 Cr | — | — |
| [Grand Oak Canyons Distillery](https://app.pivotnow.in/stock/GRANDOAK) | ₹35.48 | ₹1,841 Cr | — | — |
| [Kothari Industrial Corporation](https://app.pivotnow.in/stock/KOTIC) | ₹133.76 | ₹1,445 Cr | — | — |
| [Fedders Holding](https://app.pivotnow.in/stock/FEDDERSHOL) | ₹57.00 | ₹1,148 Cr | — | — |
| [Safe Enterprise](https://app.pivotnow.in/stock/SAFEENTP) | ₹227.20 | ₹1,059 Cr | — | — |

## Questions and answers

### What is the share price of 3B Blackbio Dx today?

3B Blackbio Dx (NSE: 3BBLACKBIO) last closed at ₹1,316.60 on 22 Oct 2026. Its 52-week high is ₹1,740.00 and its 52-week low is ₹1,085.00.

### What is the market cap of 3B Blackbio Dx?

3B Blackbio Dx's market capitalisation is ₹1,130 Cr (₹1,130 Cr) at the 22 Oct 2026 close, ranking 1394th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of 3B Blackbio Dx?

Return on equity was 18.1% in FY26 and return on capital employed was 22.6% in FY26 (consolidated figures).

### Is 3B Blackbio Dx a debt-free company?

3B Blackbio Dx is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.

### What were 3B Blackbio Dx's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), 3B Blackbio Dx reported revenue of ₹35 Cr, +57.5% year on year, and net profit of ₹10 Cr, +21.9% year on year.

### What is the shareholding pattern of 3B Blackbio Dx?

As of 30 Jun 2026: promoters 40.95%, foreign institutions 2.50%, domestic institutions 2.15%, non-institutions 54.40%.

### Who are 3B Blackbio Dx's competitors?

The listed Diversified companies closest to 3B Blackbio Dx by market cap are BOMDYEING, Sika Interplant Systems, Grand Oak Canyons Distillery, Kothari Industrial Corporation, Fedders Holding and Safe Enterprise.

### Is 3B Blackbio Dx a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out 3B Blackbio Dx's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on 3BBLACKBIO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.